SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3357RNAi VEGF-A Figured this was coming sooner or later. Once every 6m shot would BioBait-8/23/2021
3356August 4 REGEN-COV use is increasing across the U.S. following the latest surgeBioBait-8/20/2021
3355Same protease involved in viral entry for Cov2 by cleaving spike protein. A sucCuttingEdge Bio-8/16/2021
3354TMPRSS2 as target is from 2014-SARS!Miljenko Zuanic-8/16/2021
3353The only problem with this approach is people want a fast-acting pill that can bCuttingEdge Bio-8/15/2021
3352ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS Interesting- treating orBioBait-8/15/2021
3351NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES POSITIVE PHASE 3 TRIAL RESULTS FOR REGBioBait-8/4/2021
3350Now I see your point. For others, here is the release, investor.regeneron.com. A.J. Mullen-8/2/2021
3349Try the company press release? "In those who require repeat dosing for ongoCuttingEdge Bio-8/2/2021
3348That's the reverse of what was stated in the link I posted: Regeneron saidA.J. Mullen-8/2/2021
3347So the immunocompromised should live in fear and have no protection from covid? CuttingEdge Bio-8/2/2021
3346"pre-exposure prophylaxis " may make people fell safe/secure...and thaMiljenko Zuanic-8/1/2021
3345This is only for post-exposure prophylaxis, or "who are at high risk of expCuttingEdge Bio-8/1/2021
3344Thats not what I read. finance.yahoo.com FDA okays Regeneron COVID-19 antibody A.J. Mullen-8/1/2021
3343REGN got denied by FDA for EUA expansion into pre-exposure prophylaxis. Wtf? On CuttingEdge Bio-8/1/2021
3342q2 only. going forward: + new indications + reordering + add additional countriBioBait-7/31/2021
3341Is that your estimate for the 2021 year collaboration revenue? Or just for the sdaChosen1-7/25/2021
3340roche cov2 647usd for h1 - 177usd for q1 = 470 for q2 @38% (based on q1) = $17BioBait-7/22/2021
3339diletedMiljenko Zuanic-7/19/2021
3338What a strange comment. Alnylam's platform is designed for gene silencing,CuttingEdge Bio-7/19/2021
3337It is easy to generate "candidate" and move them "forwards" Miljenko Zuanic-7/19/2021
3336You sound upbeat with your ANLY and REGN collaboration so why do you not predictFelix B-7/16/2021
3335< then the difference in profit sharing will not factor into that decision ofMiljenko Zuanic-7/15/2021
3334Yes, that's a fair point that I should have added too. We are only talking CuttingEdge Bio-7/15/2021
3333Perhaps a flop commercially but SNY was critical in funding REGN in the early daFelix B-7/14/2021
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News